Camp4 Therapeutics Corp 8-K

What Happened
Camp4 Therapeutics Corporation (CAMP) filed a Form 8-K (Regulation FD disclosure) on January 9, 2026 to announce it updated its corporate/investor presentation. The presentation is available on the "Investors" section of the company website and was furnished with the 8-K as Exhibit 99.1. The report was signed by President and CEO Josh Mandel-Brehm.

Key Details

• Filing date: January 9, 2026 (Form 8-K, Item 7.01: Regulation FD Disclosure).
• Updated corporate presentation posted at https://investors.camp4tx.com and furnished as Exhibit 99.1.
• Report signed by Josh Mandel-Brehm, President and Chief Executive Officer.

Why It Matters
An updated investor presentation can contain refreshed information on the company’s business overview, pipeline, clinical or development milestones, strategy and investor messaging. Retail investors should review the newly posted slides on Camp4’s investor site to see any changes to program status, timelines or corporate priorities; the 8-K itself does not include financial results or guidance.